AKT1 and hepatocellular carcinoma: Next, using LY294002 (an inhibitor of the Akt signaling pathway) and rapamycin (an inhibitor of the mTOR signaling pathway), we found that blocking the Akt and mTOR pathway in HCC cells decreased EphA1-activated SDF-1 expression (Fig. 5c).